Major Funds Amplify Stakes in Puma Biotechnology

Institutional confidence in Puma Biotechnology appears to be mounting, as evidenced by substantial position increases from several major investment houses. A notable move came from American Century Companies Inc., which boosted its holdings by 21.2% during the first quarter. This strategic acquisition brings the total value of its investment in the biopharmaceutical company to approximately $3.4 million. This activity is not isolated; other prominent firms, including Dimensional Fund Advisors and Connor Clark & Lunn Investment Management, have similarly expanded their stakes in recent quarters, signaling a broader trend of institutional accumulation.

Strong Quarterly Performance Drives Confidence

The growing investor interest coincides with a robust financial turnaround for Puma Biotechnology in the second quarter of 2025. The company reported a net income of $5.9 million, or $0.12 per share, marking a decisive shift from a net loss of $4.5 million recorded in the same period last year.

This return to profitability was supported by an 11.4% surge in total revenue, which reached $52.44 million. The growth was primarily fueled by robust sales of its flagship product, NERLYNX®. Net product revenue for the drug climbed 11.3% to $49.19 million, with an additional $3.25 million contributed by licensing income.

Operationally, the company demonstrated disciplined financial management. Total operating costs and expenses were reduced to $45.8 million, down from $49.3 million in the prior year’s quarter. Conversely, research and development expenses saw an increase to $15.5 million, largely attributable to heightened activity within the Alisertib clinical trial program.

Should investors sell immediately? Or is it worth buying Puma Biotechnology?

Upcoming Pipeline Catalysts on the Horizon

The progression of Puma’s drug pipeline remains a critical focal point for the market. Company leadership has reaffirmed its full-year 2025 guidance, projecting total revenue to land between $212 million and $222 million, with anticipated net income in the range of $23 million to $28 million.

Significant clinical milestones are approaching, with interim data readouts from two Phase II studies for Alisertib expected in the fourth quarter of 2025. These trials, known as ALISCA™-Breast1 and ALISCA™-Lung1, represent potential value-driving events. Positive outcomes from these studies could have a material and lasting impact on the company’s valuation.

Analysts Maintain a Bullish Outlook

Market analysts continue to express cautious optimism regarding Puma’s prospects. HC Wainwright & Co. has reiterated its Buy recommendation, accompanying it with a $7.00 price target. This projection suggests substantial upside potential from current trading levels. The consensus twelve-month price target among covering analysts also stands at $7.00.

Key Financial Metrics at a Glance:
* Q2 2025 Net Income: $5.9 million (profitable turnaround achieved)
* Revenue Growth: +11.4% to $52.44 million
* NERLYNX® Quarterly Sales: $49.19 million
* 2025 Annual Forecast: Projected revenue of $212-$222 million
* Pipeline Update: Interim Alisertib study data anticipated in Q4 2025